A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria

BACKGROUND: Asymmetric dimethylarginine (ADMA) is a competitive inhibitor of endothelial nitric oxide synthase (eNOS) that is associated with endothelial dysfunction, and is a risk marker for cardiovascular disease, a significant problem in Type 1 diabetes. The aim of the present study was to measur...

Descripción completa

Detalles Bibliográficos
Autores principales: Sibal, Latika, Agarwal, Sharad C, Schwedhelm, Edzard, Lüneburg, Nicole, Böger, Rainer H, Home, Philip D
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2698883/
https://www.ncbi.nlm.nih.gov/pubmed/19486510
http://dx.doi.org/10.1186/1475-2840-8-27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2698883/
https://www.ncbi.nlm.nih.gov/pubmed/19486510
http://dx.doi.org/10.1186/1475-2840-8-27

Ejemplares similares